Walleye Capital’s Traws Pharma TRAW Stock Holding History

Walleye Capital’s Portfolio TRAW Stock Details TRAW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,911	Closed	-$374	–	2360
2021 Q3	$374	Buy	+3,911	New	+$504K	0.01%	919

Other funds holding TRAW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Walleye Capital's TRAW Position: Q4 2021 in Review

Walleye Capital sold out of Traws Pharma (TRAW) in Q4 2021, closing a stake of 3,911 shares — an estimated $374 sold.

Walleye Capital first reported a position in TRAW in Q3 2021 and held it in 1 quarter. The position peaked at $374 in Q3 2021. 34 funds tracked by Wall St. Rank hold TRAW as of Q4 2021.

Walleye Capital reported no remaining Traws Pharma position as of Q4 2021 after selling out during the quarter.
Walleye Capital sold 3,911 Traws Pharma shares in Q4 2021, an estimated $374.
Walleye Capital first reported a position in Traws Pharma in Q3 2021 and held it in 1 quarter.
Walleye Capital's Traws Pharma position peaked at $374 in Q3 2021.
34 funds tracked by Wall St. Rank held Traws Pharma as of Q4 2021.

Based on Walleye Capital's 13F filing for Q4 2021, filed 3 Mar 2022.